Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 49

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 49
---
 | our ability to meet anticipated milestones in        
 the development and testing of the relevant product; |

| · | our ability to be a leader in the development 
 of phage-based therapeutics;                  |

| · | the expected use of proceeds from the $26.2 million 
 DoD award;                                          |

| · | the effects of government regulation and regulatory                                                                                       
 developments, and our ability and the ability of the third parties with whom we engage to comply with applicable regulatory requirements; |

| · | the accuracy of our estimates regarding future                              
 expenses, revenues, capital requirements and need for additional financing; |

| · | our expectations regarding future planned expenditures; |

| · | our ability to achieve and maintain effective                                                       
 internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act; |

| · | our ability to obtain, maintain and successfully                                                                  
 enforce adequate patent and other intellectual property protection of any of our products and product candidates; |

| · | our ability to protect our intellectual property, 
 including pending and issued patents;             |

| · | our ability to operate our business without infringing 
 the intellectual property rights of others;            |

| · | our ability to advance our clinical development 
 programs;                                       |

| · | the effects of ongoing conflicts between Ukraine                                                               
 and Russia and in the Middle East, the recent and potential future bank failures or other geopolitical events; |

| · | the potential                                                                                           
 economic and regulatory impacts on the biotechnology, pharmaceutical and drug manufacturing industries; |

| · | the effects                                                                 
 of artificial intelligence on our business and the industry as a whole; and |

| · | statements of belief and any statement of assumptions 
 underlying any of the foregoing.                      |

In some cases, you can identify
these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,”
“will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect
our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this
prospectus and are subject to risks and uncertainties. Moreover, we operate in a very competitive and rapidly changing environment. New
risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all